Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta‐analysis of randomised controlled trials

No statistically significant differences were found in the efficacy, primary safety and immunogenicity between biosimilar insulins and reference insulins. These findings support biosimilar insulins' adoption to enhance treatment access and cost-effectiveness.